View Financial HealthNeurone Studio 配当と自社株買い配当金 基準チェック /06Neurone Studio配当金を支払った記録がありません。主要情報n/a配当利回り-21.9%バイバック利回り総株主利回り-21.9%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Feb 11Neurone Studio S.A. to Report Q4, 2025 Results on Feb 13, 2026Neurone Studio S.A. announced that they will report Q4, 2025 results on Feb 13, 2026分析記事 • Jan 04A Look At The Fair Value Of Neurone Studio S.A. (WSE:NRS)Key Insights Using the 2 Stage Free Cash Flow to Equity, Neurone Studio fair value estimate is zł1.30 With zł1.20 share...Buy Or Sell Opportunity • Dec 16Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 27% to zł1.02. The fair value is estimated to be zł1.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 165% over the last 3 years. Earnings per share has grown by 26%.Buy Or Sell Opportunity • Dec 01Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 15% to zł1.10. The fair value is estimated to be zł1.42, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 165% over the last 3 years. Earnings per share has grown by 24%.お知らせ • Nov 11Neurone Studio S.A. to Report Q3, 2025 Results on Nov 13, 2025Neurone Studio S.A. announced that they will report Q3, 2025 results on Nov 13, 2025New Risk • Sep 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł213k free cash flow). Shares are highly illiquid. Revenue is less than US$1m. Market cap is less than US$10m (zł3.87m market cap, or US$1.07m). Minor Risk Shareholders have been diluted in the past year (26% increase in shares outstanding).New Risk • Sep 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł213k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł213k free cash flow). Shares are highly illiquid. Revenue is less than US$1m. Market cap is less than US$10m (zł2.85m market cap, or US$786.9k).New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł324k free cash flow). Shares are highly illiquid. Negative equity (-zł141k). Revenue is less than US$1m. Market cap is less than US$10m (zł3.51m market cap, or US$868.5k). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).お知らせ • Jun 18Neurone Studio S.A., Annual General Meeting, Jul 11, 2024Neurone Studio S.A., Annual General Meeting, Jul 11, 2024.お知らせ • Jan 31+ 3 more updatesNeurone Studio S.A. to Report Q3, 2024 Results on Nov 14, 2024Neurone Studio S.A. announced that they will report Q3, 2024 results on Nov 14, 2024New Risk • Aug 25New major risk - Negative shareholders equityThe company has negative equity. Total equity: -zł6.8k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł329k free cash flow). Shares are highly illiquid. Negative equity (-zł6.8k). Revenue is less than US$1m (zł250 revenue, or US$60.0). Market cap is less than US$10m (zł4.39m market cap, or US$1.06m). Minor Risk Shareholders have been diluted in the past year (3.4% increase in shares outstanding).お知らせ • Jun 04Neurone Studio S.A., Annual General Meeting, Jun 30, 2023Neurone Studio S.A., Annual General Meeting, Jun 30, 2023, at 11:00 Central European Standard Time.お知らせ • Jan 26+ 2 more updatesNeurone Studio S.A. to Report Q3, 2023 Results on Nov 13, 2023Neurone Studio S.A. announced that they will report Q3, 2023 results on Nov 13, 2023Is New 90 Day High Low • Feb 12New 90-day low: zł3.70The company is down 21% from its price of zł4.70 on 13 November 2020. The Polish market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Entertainment industry, which is down 17% over the same period.Is New 90 Day High Low • Oct 21New 90-day low: zł4.74The company is down 18% from its price of zł5.75 on 23 July 2020. The Polish market is down 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Entertainment industry, which is down 3.0% over the same period.決済の安定と成長配当データの取得安定した配当: NRSの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: NRSの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Neurone Studio 配当利回り対市場NRS 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (NRS)n/a市場下位25% (PL)2.6%市場トップ25% (PL)7.2%業界平均 (Entertainment)1.4%アナリスト予想 (NRS) (最長3年)n/a注目すべき配当: NRSは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: NRSは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: NRSの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: NRSが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YPL 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 12:11終値2026/03/18 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Neurone Studio S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Feb 11Neurone Studio S.A. to Report Q4, 2025 Results on Feb 13, 2026Neurone Studio S.A. announced that they will report Q4, 2025 results on Feb 13, 2026
分析記事 • Jan 04A Look At The Fair Value Of Neurone Studio S.A. (WSE:NRS)Key Insights Using the 2 Stage Free Cash Flow to Equity, Neurone Studio fair value estimate is zł1.30 With zł1.20 share...
Buy Or Sell Opportunity • Dec 16Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 27% to zł1.02. The fair value is estimated to be zł1.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 165% over the last 3 years. Earnings per share has grown by 26%.
Buy Or Sell Opportunity • Dec 01Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 15% to zł1.10. The fair value is estimated to be zł1.42, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 165% over the last 3 years. Earnings per share has grown by 24%.
お知らせ • Nov 11Neurone Studio S.A. to Report Q3, 2025 Results on Nov 13, 2025Neurone Studio S.A. announced that they will report Q3, 2025 results on Nov 13, 2025
New Risk • Sep 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł213k free cash flow). Shares are highly illiquid. Revenue is less than US$1m. Market cap is less than US$10m (zł3.87m market cap, or US$1.07m). Minor Risk Shareholders have been diluted in the past year (26% increase in shares outstanding).
New Risk • Sep 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł213k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł213k free cash flow). Shares are highly illiquid. Revenue is less than US$1m. Market cap is less than US$10m (zł2.85m market cap, or US$786.9k).
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł324k free cash flow). Shares are highly illiquid. Negative equity (-zł141k). Revenue is less than US$1m. Market cap is less than US$10m (zł3.51m market cap, or US$868.5k). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
お知らせ • Jun 18Neurone Studio S.A., Annual General Meeting, Jul 11, 2024Neurone Studio S.A., Annual General Meeting, Jul 11, 2024.
お知らせ • Jan 31+ 3 more updatesNeurone Studio S.A. to Report Q3, 2024 Results on Nov 14, 2024Neurone Studio S.A. announced that they will report Q3, 2024 results on Nov 14, 2024
New Risk • Aug 25New major risk - Negative shareholders equityThe company has negative equity. Total equity: -zł6.8k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł329k free cash flow). Shares are highly illiquid. Negative equity (-zł6.8k). Revenue is less than US$1m (zł250 revenue, or US$60.0). Market cap is less than US$10m (zł4.39m market cap, or US$1.06m). Minor Risk Shareholders have been diluted in the past year (3.4% increase in shares outstanding).
お知らせ • Jun 04Neurone Studio S.A., Annual General Meeting, Jun 30, 2023Neurone Studio S.A., Annual General Meeting, Jun 30, 2023, at 11:00 Central European Standard Time.
お知らせ • Jan 26+ 2 more updatesNeurone Studio S.A. to Report Q3, 2023 Results on Nov 13, 2023Neurone Studio S.A. announced that they will report Q3, 2023 results on Nov 13, 2023
Is New 90 Day High Low • Feb 12New 90-day low: zł3.70The company is down 21% from its price of zł4.70 on 13 November 2020. The Polish market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Entertainment industry, which is down 17% over the same period.
Is New 90 Day High Low • Oct 21New 90-day low: zł4.74The company is down 18% from its price of zł5.75 on 23 July 2020. The Polish market is down 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Entertainment industry, which is down 3.0% over the same period.